Sanifit received a grant in the latest call of the Torres Quevedo program by getting the second best national rating.
Torres Quevedo grants belong to the State Program for the Promotion of Talent and Employability in R+D of the Spanish Ministry of Economy and Finance. Its aim is to encourage the hiring of doctors by companies and other research centres to develop industrial research projects.
Sanifit is dedicated to the development of therapeutic solutions for the treatment of diseases related to calcium. Specifically, SNF472 is an experimental drug for the treatment of cardiovascular disease in haemodialysis patients. The first indication for SNF472 is the treatment of calciphylaxis, a rare disease affecting between 1 and 4% of dialysis patients, with an average life expectancy of 1 year from diagnosis. Sanifit received orphan drug designation for SNF472 (from EMA and FDA) and has already completed all Phase I studies in healthy volunteers. As a consequence of receiving the Torres Quevedo grant, Dr. Canals has joined the Sanifit team as Project Manager for preclinical and clinical activities.